Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.

Launched by FONDAZIONE IRCCS POLICLINICO SAN MATTEO DI PAVIA · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial aims to collect blood and tissue samples from patients who have primary liver cancer, specifically two types called hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The study is important because liver cancer is becoming more common, and there are currently not enough effective treatments available. Over the next three years, researchers will gather these samples from patients who are starting their first round of systemic therapy (a type of treatment that works throughout the body), having surgery to remove the cancer, or undergoing a liver biopsy. These samples will help scientists learn more about the disease and develop new therapies.

To participate in this trial, patients need to have a diagnosis of primary liver cancer and must be eligible to start their first-line treatment or have surgery. Participants should be between the ages of 18 and 75 and must give their consent to join the study. During the trial, blood samples will be taken at specific times during treatment, and tissue samples will be collected from surgeries or biopsies, as long as they are not needed for other medical purposes. This study is currently recruiting participants, and it's a great opportunity to contribute to research that could lead to better treatments for liver cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary liver cancer (hepatocellular carcinoma or intrahepatic cholangiocarcinoma)
• • Signed informed consent
• • Patient eligible to start first-line systemic therapy
• • Patient eligible for surgical resection
• Exclusion Criteria:
• • Concurrent conditions with a life expectancy of less than 12 months
• • Autoimmune or chronic inflammatory diseases
• • Substance abuse dependency
• Other active extrahepatic malignancies or those treated within the last 3 years, except for the following exceptions:
• • Tumors resected with curative intent and with no evidence of disease recurrence for \>3 years prior to signing the informed consent, considered at low risk of recurrence
• • Adequately resected non-melanoma skin cancers or lentigo maligna with no evidence of metastasis
• • Adequately treated carcinoma in situ of the cervix with no evidence of recurrence
• • Prostatic intraepithelial neoplasia with no evidence of infiltrative disease
• • Adequately treated non-invasive papillary urothelial tumors or urothelial carcinoma in situ
• • HIV infection
• • Lack of patient cooperation or failure to sign the informed consent